血清肿瘤标志物CA15-3对Her-2阳性乳腺癌术后化疗疗效的评估价值  

Role of serum tumor marker CAI5-3 in predicting response during chemotherapy after surgery in Her-2-positive breast cancer

作　　者：陈晓华 曹小龙 陈逢生[2] 陈旭坚[2] 罗荣城[2] 

机构地区：[1]番禺中心医院肿瘤科,广东广州510515 [2]广州南方医科大学附属南方医院肿瘤中心,广东广州510515

出　　处：《分子诊断与治疗杂志》2014年第3期177-182,共6页Journal of Molecular Diagnostics and Therapy

基　　金：广东省自然科学博士启动基金(S2011040000786)

摘　　要：目的探讨糖类抗原CA15-3在Her-2过表达乳腺癌患者术后化疗疗效监测的评估价值。方法回顾性分析66例Her-2阳性乳腺癌患者术后以蒽环类及紫杉类(44例采用Herceptin生物化疗)为基础化疗过程中血清CA15-3的变化。根据2000年RECIST标准分有效组(OR组)及无效组(NR组),通过分析两组治疗前后血清CA15-3的变化及治疗前后CA15-3下降比率绘制ROC曲线特征评估其对化疗疗效的价值。结果与治疗前相比,所有患者治疗后CA15-3血清水平显著下降(P<0.05),治疗前有效组及无效组间CA15-3血清水平无明显差异(P>0.05),有效组治疗前后CA15-3血清水平与化疗相关,治疗前后有显著差异(P<0.05),而无效组治疗前后与化疗无相关,治疗前后无显著差异(P>0.05),治疗前后CA15-3下降比率绘制ROC曲线,其曲线下面积为0.527。采用Herceptin的生物化疗患者,与治疗前相比治疗后CA15-3血清水平亦显著下降(P<0.05),治疗前有效组及无效组间CA15-3血清水平亦无明显差异(P>0.05),有效组治疗前后CA15-3血清水平与化疗相关,治疗前后有显著性差异(P<0.05),而无效组治疗前后血清CA15-3水平与化疗相关(P<0.05),但无显著性差异(P>0.05),采用治疗前后CA15-3下降比率绘制ROC曲线,其曲线下面积为0.618。结论 CA15-3在Her-2阳性乳腺癌患者术后化疗疗效有一定预测作用,在Herceptin为基础的生物化疗中有一定的敏感性及特异性。Objective To evaluate the role of serum tumor marker CA15-3 in predicting response during chemotherapy after surgery in Her-2 positive breast cancer patients. Methods The level change of serum tumor marker CA15-3 was analyzed retrospectively in 66 Her-2 positive breast caner patients during chemotherapy （base on Paclitaxel or anthracene, 44 patients with Herceptin biochemotherapy） after surgery. The patients were divided into two groups： responsive group（OR group）and unresponsive group（NR group） according to response evaluation criteria in solid tumors. The serum level change of CA15-3 and the ROC curve base on the decrease rate of CA15-3 serum level before and after chemotherapy were analyzed and its role in predicting response was evaluated. Results CA15-3 serum level were significant decreased in all patients after chemotherapy（P〈0.05）. There are not significant different of serum level of CA15-3 between OR and NR groups before chemotherapy after surgery （P〉0,05）. There are significant different of serum level of CA15-3 in the OR group before and after chemotherapy（P〈0.05） while it was not significant in the NR group（P〉0.05）, and the level of CA15-3 has the relationship with chemotherapy effect in the OR group while has not relationship in the NR group. ROC curve was made base on the decrease rate of CA15-3 serum level before and after chemotherapy and the area was 0.527. Base on Herceptin biochemotherapy patients, their CA15-3 serum level were also significant decreased in all patients after therapy （P〈0.05）. There are also not significant different of serum level of CA15-3 between OR and NR groups before biochemotherapy after surgery（P〉0.05）. There are also significant different of serum level of CA15-3 in the OR group before and after biochemotherapy （P〈0.05） and it was not significant in the NR group （P〉0.05）. The level of CA15-3 has the relationship with biochemotherapy effect in the OR group and NR group. ROC curve was made base on the decreas

关 键 词：乳腺癌 辅助化疗 CA15-3 疗效评估 

分 类 号：R737.9[医药卫生—肿瘤]